Other News To Note
Wednesday, January 11, 2012
Alchemia Ltd., of Brisbane, Australia, said it randomized the first patient in its pivotal Phase III study of HA-Irinotecan, its lead cancer drug that uses the firm's HyACT technology to target irinotecan directly to cancer cells.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.